Article
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Molecular cancer - 5 Oct 2012
Byron Sara A, Loch David C, Wellens Candice L, Wortmann Andreas, Wu Jiayi, Wang John, Nomoto Kenichi, Pollock Pamela M
Abstract excerpt
BACKGROUND: Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illustrated recently by the clinical experience with vemurafenib. Such acquired resistance appears to be the result of parallel pathway activation, such as PI3K, to...
Topics
- Animals
- Antineoplastic Agents
- Cell Survival
- Chromones
- Drug Resistance, Neoplasm
- Female
- Humans
- Lactones
- MAP Kinase Kinase Kinases
- Melanoma
- Mice